Epigenetics in Human Cancer: Emerging Biomarkers and Therapeutic Targets
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 48
Special Issue Editor
Interests: cancer biology; translational research; breast cancer; epigenetics; drug resistance; cancer stem cells; epithelial-mesenchymal transition; tumor metastasis; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Beyond genetic alterations, epigenetic changes are increasingly recognized as critical drivers in the initiation, progression, and therapeutic resistance of human cancers. Aberrant DNA methylation and histone modifications frequently lead to the activation of oncogenes or the silencing of tumor suppressor genes.
A growing body of evidence highlights the role of epigenetic regulators in orchestrating key cancer hallmarks, including tumorigenesis, uncontrolled proliferation, survival, metastasis, immune evasion, metabolic reprogramming, and resistance to therapy. These insights have positioned epigenetic mechanisms not only as vital elements of cancer biology but also as promising biomarkers and therapeutic targets. In particular, epigenetic-based therapies—either alone or in combination with chemotherapy, targeted therapy, or immunotherapy—are showing potential to overcome resistance and improve patient outcomes.
This Special Issue aims to provide a comprehensive overview of the epigenetic mechanisms in human cancer. We welcome original research articles and reviews that explore recent advances in cancer epigenetics, novel therapeutic targets, biomarker development, and clinical applications related to epigenetic dysregulation across various cancer types.
Topics of interest include, but are not limited to:
- DNA methylation and demethylation in cancer;
- Histone modifications and chromatin remodeling regulating cancer-associated genes;
- The role of non-coding RNAs (miRNAs, lncRNAs, circRNAs) in cancer;
- Epigenetic therapies to overcome anti-cancer drug resistance;
- Epigenetic reprogramming of the tumor microenvironment;
- Clinical applications and biomarkers based on epigenetic alterations.
We look forward to your valuable contributions to this Special Issue, hoping for them to advance the understanding and clinical application of epigenetics in oncology.
Prof. Dr. Jeong-yeon Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- epigenetics
- DNA methylation
- histone modification
- chromatin remodeling
- non-coding RNAs
- therapeutic resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
